About This Tool
The Curosurf (poractant alfa) Dose Calculator is a clinical support tool designed for healthcare professionals to determine the appropriate dosage for neonates with Respiratory Distress Syndrome (RDS). It simplifies the calculation process by considering patient weight, dosing scenario (initial or repeat), and available vial sizes to minimize waste and ensure accurate administration.
Outputs Explained
After entering the required patient information, the calculator provides the following key outputs:
- Total Dose (mg): The total amount of poractant alfa in milligrams, calculated based on the patient's weight in kilograms and the selected dose strength (2.5 mL/kg or 1.25 mL/kg).
- Total Volume to Administer (mL): The final volume to be drawn into a syringe for administration. Curosurf has a concentration of 80 mg/mL.
- Vials to Prepare: A recommendation for the combination of 1.5 mL and/or 3.0 mL vials that meets the required volume while minimizing waste.
- Volume per Aliquot (mL): The total volume divided by the selected number of aliquots (2 or 4), which is critical for the staged administration process.
How to Use the Calculator
- Enter Patient Weight: Input the neonate's weight. You can switch between kilograms (kg) and grams (g) using the toggle buttons.
- Select Dose Type: Choose 'Initial / Rescue' for the first dose (2.5 mL/kg) or 'Repeat Dose' for subsequent doses (1.25 mL/kg).
- Indicate Available Vials: Check the boxes corresponding to the vial sizes (1.5 mL and/or 3.0 mL) you have in stock.
- Choose Aliquots: Select whether the total dose will be divided into 2 or 4 aliquots for administration.
- Calculate: Click the 'Calculate Dose' button to see the results. Use the 'Reset' button to clear all fields.
Dosing Overview
Curosurf is an intratracheal suspension administered to premature infants with RDS. The dosing regimen is weight-based:
- Initial Dose: The recommended starting dose is 2.5 mL/kg birth weight.
- Repeat Doses: Up to two repeat doses of 1.25 mL/kg birth weight may be administered. Repeat doses should be given at least 12 hours apart in infants who remain on mechanical ventilation and require supplemental oxygen.
The total dose is divided into aliquots and administered into the trachea to ensure even distribution in the lungs. Vials should be warmed to room temperature before use and gently turned upside down to create a uniform suspension. Do not shake.
Switching Surfactants
Switching between different surfactant preparations (e.g., from beractant to poractant alfa) during the treatment course for RDS is not standard practice and lacks extensive clinical data. Any decision to switch should be based on a thorough clinical evaluation by the attending neonatologist, considering the patient's response to the initial therapy and institutional guidelines.
Missed or Delayed Dose
Curosurf is administered in a controlled, in-patient setting by trained medical personnel. A "missed dose" in the conventional sense is not applicable. The timing of repeat doses is determined by ongoing clinical assessment, including oxygenation and ventilation requirements. If a repeat dose is clinically indicated but delayed, it should be administered as soon as it is deemed necessary and safe by the medical team.
Safety Alerts
Administration of Curosurf should only occur in a highly supervised clinical setting with immediate availability of staff experienced in neonatal intubation and resuscitation. Transient adverse events may occur during administration, including:
- Bradycardia
- Hypotension
- Oxygen desaturation
- Endotracheal tube blockage
Continuous monitoring of heart rate, oxygen saturation, and chest wall movement is essential during and after administration. Dosing should be paused if adverse reactions occur, and administration should resume only after the infant is stable.
Frequently Asked Questions
What is the concentration of Curosurf?
Curosurf (poractant alfa) is supplied as a suspension with a concentration of 80 mg of phospholipids per mL.
Why does the calculator have a weight range warning?
The tool includes a validation check for weights between 0.4 kg and 10 kg. This range covers the vast majority of neonatal and infant cases where Curosurf is used. Weights outside this range may require special consideration and clinical judgment.
What should I do if I only have one vial size in stock?
Simply uncheck the vial size that is not available. The calculator will then determine the number of vials needed using only the size you have in stock.
How does the calculator decide which vials to use?
The algorithm calculates the combination of available vials that meets the required total volume with the least amount of waste. If two combinations result in the same waste, it prioritizes the one using fewer total vials.
Why is the dose administered in aliquots?
Dividing the dose into aliquots and administering them with the infant in different positions helps ensure the surfactant is distributed evenly throughout both lungs, which is critical for its efficacy.
Can I use the leftover Curosurf in a vial?
No. Curosurf vials are for single use only. Once a vial is opened, any unused portion of the suspension should be discarded.
Does this tool calculate doses for indications other than RDS?
This calculator is specifically designed for the approved dosing regimens for neonatal Respiratory Distress Syndrome (RDS) as described in the official prescribing information.
Is this calculator a substitute for the official package insert?
No. This tool is for informational and educational purposes only. It is not a substitute for clinical judgment or the official prescribing information, which should always be consulted for complete dosing, administration, and safety details.
References
- U.S. Food and Drug Administration (FDA). CUROSURF (poractant alfa) Intratracheal Suspension Prescribing Information.
- European Medicines Agency (EMA). Curosurf - European Public Assessment Report (EPAR).
- Chiesi USA, Inc. Curosurf Official Healthcare Professional Website.
- Sweet DG, et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2022 Update. Neonatology. 2023;120(1):1-23. doi: 10.1159/000528914.
